Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study

Gemcitabine and oxaliplatin (GEMOX) are active as first-line therapy against advanced pancreatic cancer. This study aims to evaluate the activity and tolerability of this combination in patients refractory to standard gemcitabine (GEM). A total of 33 patients (median age of 57) were included with lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Demols, A, Peeters, M, Polus, M, Marechal, R, Gay, F, Monsaert, E, Hendlisz, A, Van Laethem, J L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361170/
https://www.ncbi.nlm.nih.gov/pubmed/16434988
http://dx.doi.org/10.1038/sj.bjc.6602966

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361170/
https://www.ncbi.nlm.nih.gov/pubmed/16434988
http://dx.doi.org/10.1038/sj.bjc.6602966

Ejemplares similares